Volume : 08, Issue : 08, August – 2021
Title:
51.REVIEW ON SARS COV-2(COVID-19)
Authors :
AjinkyaR. Pawar, Vaishnavi P.Taskar, Sagar B Kadam, Sanika R. Bhalerao, Jaiprakash Kokane, Bhavana Kokane, Sonali Kawade
Abstract :
Severe Acute Respiratory Syndrome Corona virus -2(SARS-COV-2)is highly transmissible and pathogenic Corona virus,has caused a pandemic of acute respiratory disease named Corona virus disease 2019(Covid-19) which threaten human health and public safety. On January 30.2020 World Health Organisation declared the outbreak as a Public Health Emergency of international concern. In these review we describe basic virology of SARS-COV-2, including diagnosis, treatment. We summarise current knowledge of clinical epidemiology and pathological features of COVID-19 as well as Immune response, management of disease, control and prevention strategies, progress in vaccination for SARS COV-2.
Keywords- Severe acute respiratory syndrome, Corona virus -19, epidemiology, pathology, public health, prevention strategies.
Cite This Article:
Please cite this article in press AjinkyaR. Pawar et al., Review On SARS COV-2 (COVID-19)., Indo Am. J. P. Sci, 2021; 08(08).
Number of Downloads : 10
References:
1. .Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating COVID-19? J Infect Dis 2020.
2. Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. JAMA 2020; 323:1837.
3. Stadnytskyi V, Bax CE, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Proc Natl AcadSci USA 2020; 117:11875.
4. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient.
5. Calistri P, Amato L, Puglia I, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J Infect Dis 2021; 105:753.
6. Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 2020; 369:1603.
7. Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021; 372:n579.
8. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, et al. Increased mortality in community- tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021; 593:270.
9. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021; 371:1152.
10. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. UNPUBLISHED. https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1.full.pdf (Accessed on January 25, 2021).